Entrada Therapeutics

Update in progress

TRDA (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on delivering medicines that target intracellular proteins once considered inaccessible. Its platform uses an Endosomal Escape Vehicle to enable intracellular delivery, with a pipeline of genetic medicines aimed at neuromuscular and inherited retinal diseases. Preclinical programs include ENTR-601-44, ENTR-601-45 and VX-670. Incorporated in 2016 and based in Boston, it was formerly CycloPorters, Inc., changing its name in 2017.

Company score

Sentiment: 0.05; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.04; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive